TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent of Subjects With no Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Lp(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VLDL-TG metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Chronic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Suicide Cognitions Scale (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression Anxiety and Stress Scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in severity score of impetigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Negative predictive value of drug provocation tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in QuickDASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sexual encounter profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in trained manual dexterity of the dominant hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of goal calories provided
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete healing of anal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of Herpes Simplex Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Unplanned Hospital Admissions for Cardiac Reasons
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Death of Cardiovascular Causes
Endpoint domain: Mortality/survival
Primary endpoint: Progression to Chronic Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: operative time from incision to closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cohen-Mansfield Agitation Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of Evacetrapib (Fasted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Evacetrapib (Fasted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Fraction of Cytotoxic T-lymphocytes (FCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average Specific Cytotoxic T-lymphocyte Frequency Ratio (ASCTFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Baseline of Fraction of Cytotoxic T-lymphocytes (FCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in 2-week rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nystagmus intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vestibulo-ocular reflex gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of exhaled breath condensate hydrogen peroxide (EBC H2O2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in school readiness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of somatic BRCA mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Montgomery-Asberg Depression Scale (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Institutionalization
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Engagement in serious game sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Initial discharge prescription oral morphine equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Recovery of Radioactive Dose in Urine and Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-t) for Total Radioactivity in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-t) for Eribulin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of true negative rapid immunochromatographic strep test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Expression of MDR1/P-glycoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Menstrual Bleeding to Normal or Below Normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of packs of fixed combination prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants With Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Treatment-Emergent Adverse Events (TEAEs) During Phase 1b and 2
Endpoint domain: Adverse events/effects
Primary endpoint: Best Overall Response in Phase 2 as Assessed by Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h urinary DHBA:DHPPA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Burdens and Benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Ease of Use, Usefulness and Trustworthiness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of pathological complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Confident in the Use of EHealth Format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best-contact corrected visual acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accromio humeral distance (AHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SENP1 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PNA-R8 silencing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of sustained response (percentage of subjects who have no pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of asymptomatic portal vein thrombosis (PVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of portal hypertension (PHTN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive respiratory mechanics measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients With Grade 3-4 Febrile Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to 2. polar body extrusion in transferred embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time for disappearance of pronuclei in transferred embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time for first cleavage in transferred embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean Weight Change in Kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Weight Change From Baseline to 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasmatic 24OHC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Q angle evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyographic (EMG) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Balance Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-thrombotic treatment strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mayo-Portland Participation Index (M2PI)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Traumatic Brain Injury-Quality of Life (TBI-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Participation Assessment with Recombined Tools-Objective (PART-O)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum Measured Concentration (Cmax) of Linagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration (Cmax) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Metformin (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 levels of IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in frequency of temper outbursts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of changes to routines/plans followed by temper outbursts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in TB Lesion Sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average values of surface roughness (Ra) in implant-retained mandibular bar overdentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average values of surface roughness (Ra) in implant-retained ball joint overdentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPARCC score of spine and SI joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Case complete response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normalization of ICT or Stroop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative plasma tranexamic acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of ASP1941
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients developing AF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients developing permanent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of The PrePex System for adult male circumcision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of The PrePex System for adult male circumcision
Endpoint domain: Adverse events/effects
Primary endpoint: 24 Hour Post Operative Opioid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiologic changes during transitional circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identify the maximum tolerated dose (MTD) of vactosertib in patients with MPN enrolled on Tier 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identify dose limiting toxicities (DLTs) in patients with MPN enrolled on Tier 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Tier 2 patients who have achieved Erythropoietic response as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematological outcomes
Primary endpoint: Frequency and nature of adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with PDR001 dose interruption and/or reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-body Angular Momentum in Sagittal-plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Response to Treatment
Endpoint domain: Physiological/clinical
Primary endpoint: Death or a Specified State of Disease Progression
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in % Forced Vital Capacity (%FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: A1C less than 6.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver complications emergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Maximum Standard Uptake Value (SUVmax) at Cycle 1 Day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation Between Positron Emission Tomography (PET) Response and Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Correlation Between Positron Emission Tomography (PET) Response and Objective Response (OR)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of new ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Days Per Month of Primary Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Judgement of the treatment by the investigator and the patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: P2Y12 mediated Platelet Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in corneal nerve fibre length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of medication for global improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circadian phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Donor microchimerism quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximal Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived improvement of shape and fullness of the female breast
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adequate CD34+ stem cell numbers post-harvest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delay in diagnosing perioperative anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Meeting the Criteria for Responder
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-hepatectomy liver failure
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in nocturnal bruxism episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average Total Rhinoconjunctivitis Symptom Scores (TRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quantitative Myasthenia Gravis (QMG) Scores from Baseline to 48 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MG-specific Activities of Daily Living scale (MG-ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The proportion of patients reaching minimal manifestations (MM) or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Erlotinib treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm^2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Reporting Local and Systemic Solicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Adenosine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of eye inflammation
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of cardiac abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Admission to ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglyceride change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Right Resistive Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Right Peak Systolic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Right Diastolic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants who Experience a Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mayo Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Post-exercise Peak LVOT Gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RBC survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in post-concussive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Etanercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seropositivity rate & antibody titers for MMRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of breakthrough cases & contacts with MMRV disease(s)
Endpoint domain: Adverse events/effects
Primary endpoint: successful Calypso transponder implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: febrile rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in functional improvement of upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speed and coordination of the affected side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sensorimotor status in the two upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fruit & Vegetable Consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mammography Screening Behavior
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Colorectal cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum NGAL levels to identify renal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Seizures severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in SeHCAT retention after 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of FGF19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change in WOMAC VAS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of malarial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrence of uterovaginal and vaginal vault prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gout flare frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes